ATAI · NASDAQ
Healthcare · Biotechnology
$7.35
0.00%
Close on Sep 11, 2026
Research data through 2026-10-28
Long-term research evidence only. No price targets, no trading signals, no recommendations.
Free research · no account required
Research data through Oct 28, 2026. Research is updated periodically, not in real time.
19
of 100 · stored research reading
Stored Quality research reads 19 of 100, in the weaker band of the covered universe. This is a research reading about business durability, not a view on the share price.
Quality research measures durability of the business itself from stored fundamentals: balance-sheet strength, profitability consistency and cash generation. It is a research reading, not a prediction of future returns.
How this is measured—
Not currently available
Not currently available. Pro Investor Academy holds no current Fundamental Momentum measurement for this company.
Fundamental Momentum research measures the direction of recently reported company fundamentals compared with the company's own history. It describes reported change, not future price movement.
How this is measured13
of 100 · stored research reading
Stored Capital Returns research reads 13 of 100, recorded as weak. Stored records show 1 consecutive year of dividend payments. Share count has increased at about 22.2% a year in the stored window.
Capital Returns research measures how a company has actually returned cash to shareholders: dividend record, buyback effectiveness, dilution control and how those payments were funded.
How this is measuredNot currently available. No stored valuation ratios exist for this company.
Learn the basics of valuationInvestor intelligence
The research below is part of Investor membership. Values are withheld from this page entirely — nothing premium is loaded into it. Start the free trial and the intelligence you asked for unlocks right here.
Investor
Unlock its Pro Investor Score and ranking across the research universe.
7 days · No credit card required
Investor
Unlock Risk Intelligence, Price Risk, and Market Confirmation.
7 days · No credit card required
Investor
Unlock the Pro Research Brief with What Changed & Why, research history and tensions.
7 days · No credit card required
Investor
Unlock Pro Investor Intelligence: disclosed professional-manager and insider activity beside company research.
7 days · No credit card required
Investor
Unlock Pro Investor AI to ask questions grounded in Pro Investor Academy research and evidence.
7 days · No credit card required
Investor
Save companies and monitor how their research changes over time.
7 days · No credit card required
Explore other companies in this industry. These are objective industry neighbours, not suggested alternatives.
Pro Investor Academy continuously applies its research rules across the eligible universe and surfaces a small number of investments for deeper research when they qualify.
Research Collections
This company does not currently satisfy any collection rule. That is a stored research result, not a judgement about the business.
Browse collectionsPlain-English definitions, with the formula and the limitations of each measure.
In the company’s own words
Founded in 2025 through the strategic combination of atai Life Sciences N.V. and Beckley Psytech Limited, AtaiBeckley is a clinical-stage biotechnology company on a mission to create breakthroughs for people with difficult-to-treat mental health conditions. Our work is grounded in rigorous science to deliver meaningful outcomes for the patients we serve.
Mental health disorders are highly prevalent and estimated to affect more than one billion people globally. The economic burden of these disorders is substantial and is growing rapidly. Between 2009 and 2019, spending on mental health care in the United States increased by more than 50%, reaching $225.0 billion, and a Lancet Commission report estimates that the global economic cost will reach $16.0 trillion by 2030. While current treatments, such as selective serotonin reuptake inhibitors ("SSRIs") and serotonin-norepinephrine reuptake inhibitors ("SNRIs") are well established and effective for certain patients, approximately 65% of patients do not achieve remission of their symptoms after up to four antidepressant treatment trials, translating to a significant unmet medical need.
We aim to create breakthroughs in mental health by developing effective, rapid-acting and convenient treatments that could transform patient outcomes. We are committed to leading a new era of mental health treatment – one that not only offers relief from symptoms, but the possibility of an improved quality of life and lasting change.
We have built a diversified pipeline of investigational psychedelic-based neuroplastogens designed to address some of the most urgent unmet needs in mental health. Our programs include:
Quoted from the business section of this company’s 10-K filed March 6, 2026. Read the filing
General research only. Not personalized advice. Public filings may be delayed, amended, incomplete, or reflect positions that have changed since the reporting date.
